C4 Therapeutics, Inc.
Clinical trials sponsored by C4 Therapeutics, Inc., explained in plain language.
-
New Two-Drug attack on Hard-to-Treat myeloma enters early human tests
Disease control Recruiting nowThis early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers…
Phase: PHASE1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: experimental combo enters phase 2
Disease control Recruiting nowThis study tests a new drug, cemsidomide, combined with dexamethasone in people with multiple myeloma that has returned or not responded to at least three prior treatments. About 100 adults will receive the drug combo to see if it shrinks tumors and how safe it is. The goal is to…
Phase: PHASE2 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC